Payment overview · 2025
General Payments
$1,238.49
68 reported records · 18 companies
Healthcare provider profile · identity verified
Casey Hart Baer, NURSE PRACTITIONER
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Primary Care · HARRISBURG, PA · NPI 1154082444
Verified facts
What the public records show
CMS Open Payments records show Casey Hart Baer, NURSE PRACTITIONER received $1,238.49 in general payments during 2025 across 68 reported records.
ABBVIE INC. accounted for 15.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Rybelsus, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $188.30 | 15.2% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $174.90 | 14.1% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $135.05 | 10.9% | 11 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $103.22 | 8.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $97.71 | 7.9% | 6 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $72.40 | 5.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $64.77 | 5.2% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $58.51 | 4.7% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.04 | 4.6% | 3 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $53.63 | 4.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $49.67 | 4.0% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $42.35 | 3.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.56 | 3.0% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.81 | 2.7% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.85 | 1.6% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.28 | 1.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.76 | 1.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.68 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,238.49 | 68 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $172.55 | 10 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $103.22 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $97.71 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $95.83 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $94.29 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $94.29 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $84.82 | 8 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $72.40 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $64.77 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $64.57 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $58.51 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $57.04 | 3 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $53.63 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $49.67 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $42.35 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $39.22 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $39.22 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $39.22 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.56 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $33.81 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $32.39 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.85 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $11.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 29 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 53 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
29 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 234 | 82 |
| Lisinopril | Lisinopril | 138 | 43 |
| Gabapentin | Gabapentin | 125 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 90 | 22 |
| Amlodipine Besylate | Amlodipine Besylate | 86 | 34 |
| Montelukast Sodium | Montelukast Sodium | 84 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 82 | 31 |
| Amitriptyline Hcl | Amitriptyline Hcl | 77 | 17 |
| Buspirone Hcl | Buspirone Hcl | 74 | 16 |
| Omeprazole | Omeprazole | 73 | 28 |
| Trazodone Hcl | Trazodone Hcl | 73 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 15 |
| Famotidine | Famotidine | 70 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 62 | 15 |
| Losartan Potassium | Losartan Potassium | 62 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 62 | 24 |
| Sertraline Hcl | Sertraline Hcl | 62 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 55 | suppressed |
| Alprazolam | Alprazolam | 54 | 11 |
| Jardiance | Empagliflozin | 53 | 13 |
| Tramadol Hcl | Tramadol Hcl | 52 | 15 |
| Lorazepam | Lorazepam | 50 | 16 |
| Baclofen | Baclofen | 47 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | suppressed |
| Metformin Hcl | Metformin Hcl | 46 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 46 | 13 |
| Furosemide | Furosemide | 45 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 22 |
| Methylprednisolone | Methylprednisolone | 43 | 31 |
| Potassium Chloride | Potassium Chloride | 43 | 13 |
| Ibuprofen | Ibuprofen | 39 | 15 |
| Lamotrigine | Lamotrigine | 39 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 38 | suppressed |
| Pregabalin | Pregabalin | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Simvastatin | Simvastatin | 37 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 26 |
| Eliquis | Apixaban | 29 | 12 |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | 12 |
| Glimepiride | Glimepiride | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Bumetanide | Bumetanide | 26 | suppressed |
| Cephalexin | Cephalexin | 26 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Carvedilol | Carvedilol | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Prednisone | Prednisone | 19 | 11 |
| Fluconazole | Fluconazole | 18 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Norethindrone Acetate | Norethindrone Acetate | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 13 |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 13 |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | 11 |
| Naproxen | Naproxen | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,238.49 · 68 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AREXVY, CAPLYTA, CAPVAXIVE, COLLAGENASE SANTYL, COMIRNATY, CeQur Simplicity, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, ENFLONSIA, FANAPT, GARDASIL 9, GVOKE HYPOPEN, JARDIANCE, Korlym, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REXULTI, ROTATEQ, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VAXELIS, VRAYLAR, Wegovy, ZAVZPRET, ZENPEP, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error